|
Volumn 198, Issue 5, 2013, Pages 270-272
|
Determining research priorities for clinician-initiated trials in infectious diseases
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMINOGLYCOSIDE;
AMPICILLIN;
ANTIBIOTIC AGENT;
BETA LACTAM ANTIBIOTIC;
CEFTRIAXONE;
DAPTOMYCIN;
ERTAPENEM;
FOSFOMYCIN;
GENTAMICIN;
MEROPENEM;
PIPERACILLIN PLUS TAZOBACTAM;
VANCOMYCIN;
ARTICLE;
AUSTRALIA;
BACTERIAL ARTHRITIS;
BACTERIAL ENDOCARDITIS;
BACTERIAL INFECTION;
CELLULITIS;
CLINICAL RESEARCH;
CONTINUOUS INFUSION;
DIABETIC FOOT;
DOSAGE SCHEDULE COMPARISON;
FUNDING;
GRAM NEGATIVE INFECTION;
HUMAN;
INFECTION;
INFECTIOUS ARTHRITIS;
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION;
NEW ZEALAND;
ONLINE SYSTEM;
OSTEOMYELITIS;
PHYSICIAN;
PROSTHESIS INFECTION;
PSEUDOMONAS INFECTION;
QUESTIONNAIRE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SELF REPORT;
STAPHYLOCOCCAL BACTEREMIA;
URINARY TRACT INFECTION;
WOUND INFECTION;
|
EID: 84876768582
PISSN: 0025729X
EISSN: 13265377
Source Type: Journal
DOI: 10.5694/mja12.11703 Document Type: Article |
Times cited : (13)
|
References (9)
|